Ubrelvy

Overview

Ubrelvy (ubrogepant) is a prescription medication used for the acute treatment of migraine attacks with or without aura in adults.¹³ It belongs to a class of drugs called gepants, which are calcitonin gene-related peptide (CGRP) receptor antagonists.² CGRP is a chemical released during migraine attacks that contributes to headache pain and associated symptoms like nausea and sensitivity to light or sound.⁷ Unlike traditional pain relievers, Ubrelvy specifically targets migraine pain by blocking CGRP from binding to its receptors in the brain, helping to relieve symptoms without causing vasoconstriction.¹⁴ Approved by the FDA in 2019, it represents a newer approach to migraine management, distinct from older triptans, and is not intended for preventive use.³ It is typically prescribed when over-the-counter pain relievers like acetaminophen or aspirin are ineffective.⁴

Forms and Variations

Ubrelvy is available exclusively as oral tablets in two strengths: 50 mg and 100 mg.¹²³ These immediate-release tablets are taken by mouth and contain ubrogepant as the active ingredient, along with inactive components such as lactose monohydrate, microcrystalline cellulose, croscarmellose sodium, sodium stearyl fumarate, and vitamin E polyethylene glycol succinate.² The 50 mg dose is the standard starting option, while the 100 mg dose may be used for a second dose if needed or for those requiring higher potency.³ There are no liquid, injectable, or other formulations available. Patients should choose based on their response to the initial dose and healthcare provider guidance, as the 100 mg tablet allows for flexibility in treating more severe attacks.¹ Tablets should be swallowed whole with water, with or without food.⁶

Dosage and Administration

The recommended starting dose of Ubrelvy is 50 mg or 100 mg taken orally as soon as possible after the onset of a migraine attack.³⁶ If the migraine symptoms persist or return after 2 hours, a second dose of 50 mg or 100 mg may be taken, with a maximum of 200 mg in a 24-hour period.¹³ The dosing frequency is limited to no more than 8 doses per month to avoid medication overuse headache.³ It can be taken with or without food, though high-fat meals may delay absorption.⁶ For optimal results, administer at the first sign of migraine pain. Patients with severe hepatic or renal impairment should avoid use, and dose adjustments are required with certain moderate CYP3A4 inhibitors (reduce to 50 mg).³ Always follow prescribing information and consult a healthcare provider for personalized dosing.²

Scientific Research and Mechanism of Action

Ubrelvy"s efficacy was demonstrated in two pivotal Phase 3 clinical trials (Studies 1 and 2), where it significantly increased pain freedom at 2 hours post-dose (50 mg: 19-22%, 100 mg: 20-22% vs. placebo 12-14%) and most bothersome symptom freedom compared to placebo.³ It works by selectively antagonizing the CGRP receptor, preventing CGRP—a neuropeptide released by trigeminal nerve endings—from binding and activating pain pathways in the brain and meninges during migraine attacks.¹²⁷ This blocks vasodilation and inflammation without affecting blood vessels systemically, reducing risks associated with vasoconstrictors like triptans.⁴ The elimination half-life is 5-7 hours, supporting its acute use.³ Research confirms its role in treating acute migraine but not prevention, with consistent results across adults.³ Ongoing studies explore long-term safety, but current evidence supports its use as a targeted therapy with a favorable profile over traditional options.¹

Benefits and Potential Uses

Ubrelvy effectively treats acute migraine with or without aura, providing relief from headache pain, nausea, photophobia, and phonophobia.¹³ Key benefits include rapid onset (within 2 hours), no vasoconstriction (safer for cardiovascular patients), and suitability as an early intervention.⁴⁶ Clinical trials showed 19-22% of patients achieving pain freedom at 2 hours, superior to placebo, with sustained relief up to 24 hours for many.³ It addresses migraines unresponsive to NSAIDs or acetaminophen and offers an oral alternative to injectables.⁴ Potential uses include episodic migraines in adults, particularly those with aura symptoms like visual disturbances or tingling.¹ It does not prevent migraines or treat other headaches.⁵⁸ Benefits extend to improved quality of life by enabling quick symptom resolution without common opioid side effects.⁷

Side Effects and Risks

Common side effects of Ubrelvy include nausea (2-4%) and somnolence or drowsiness (3%).³⁶ Serious allergic reactions (hypersensitivity) can occur, with symptoms like rash, hives, swelling of face/lips/tongue/throat, wheezing, or dizziness.¹ Rare risks include Raynaud"s phenomenon (RP), involving finger/toe discoloration, pain, or numbness, which may worsen pre-existing cases and require discontinuation.⁶ Contraindications include hypersensitivity to ubrogepant and concurrent use with strong CYP3A4 inhibitors (e.g., ketoconazole).²³ Caution is advised in patients with severe liver/kidney disease, cardiovascular risks, or history of RP.³⁶ Not recommended during pregnancy/breastfeeding without provider consultation.¹

Interactions and Precautions

Ubrelvy interacts with CYP3A4 modulators: avoid strong inhibitors (e.g., ketoconazole, itraconazole, clarithromycin); reduce dose with moderate inhibitors (e.g., verapamil, cyclosporine); avoid strong inducers (e.g., rifampin, phenytoin, barbiturates).¹²³ Other interactions include antibiotics (ciprofloxacin), antifungals, seizure meds (rufinamide), HIV drugs (efavirenz), and others like fluvoxamine or quinidine.² Precautions for elderly, hepatic/renal impairment (avoid severe cases), and those with cardiovascular disease.³ Monitor patients with RP history; discontinue if symptoms appear.⁶ Not for pediatric use or migraine prevention. Inform provider before surgery or dental procedures due to potential interactions. Limit to 18 doses/month to prevent overuse.³

Impact on Biomarkers

Ubrelvy primarily affects CGRP-related pathways but has no direct impact on routine blood tests like liver enzymes, kidney function, or lipid panels in most users.³ It may indirectly influence inflammation markers during migraine resolution. Monitor for hypersensitivity via symptoms rather than labs. No significant changes in blood pressure or heart rate biomarkers due to lack of vasoconstriction.⁶ Hepatic/renal function tests recommended in at-risk patients.¹

Overdose and Toxicity

Overdose risks include exaggerated side effects like nausea, somnolence, or headache; no specific antidote exists.³ Monitor for at least 24 hours due to 5-7 hour half-life.³ Symptoms may include dizziness or fatigue. Safe upper limit is 200 mg/24 hours and 8 doses/month. Seek immediate medical help for overdose; treatment is supportive.¹³

Disclaimer

The information provided in this document is for educational purposes only and does not constitute medical advice. It is essential to consult with a qualified healthcare professional for any health concerns or before making any decisions related to your health or treatment.